Effectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis
Open Access
- 1 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (4) , e18890
Abstract
Rationale: Takayasu arteritis (TA) is a systemic large-vessel vasculitis which can be accompanied by the symptoms associated with vascular stenosis. Patient concerns: We describe 2 female juveniles with TA who presented with progressive intermittent claudication. Diagnosis: Contrast-enhanced computed tomography (CT) revealed the stenosis of femoral arteries and increased levels of C-reactive protein (CRP), and serum amyloid A (SAA) were noted in both patients. According to European league against rheumatism consensus criteria for the diagnosis of TA was confirmed in both patients. Interventions: Both patients had shown resistance to glucocorticoids and treated with tocilizumab (TCZ) (subcutaneous injections, 162 mg/week). Outcomes: These treatments improved claudication symptoms. Follow-up imaging by enhanced CT revealed restoration of advanced stenosis of the femoral arteries in both patients. They achieved normalization of levels of the acute-phase reactants CRP and SAA. Serum levels of interleukin-6 were increased transiently after TCZ injection, but declined to within normal ranges at 12 weeks. Lessons: Juvenile patients with TA presenting with advanced stenosis of the femoral arteries are not rare. The clinical courses of our patients suggested the beneficial effects of TCZ against the progressive vascular stenosis observed in refractory TA.Keywords
Funding Information
- Japan Society for the Promotion of Science (17K09981))
This publication has 21 references indexed in Scilit:
- Advances in the diagnosis, assessment and outcome of Takayasu’s arteritisClinical Rheumatology, 2012
- Takayasu Arteritis: Diagnosis, Treatment and PrognosisInternational Reviews of Immunology, 2012
- Takayasu arteritis—advances in diagnosis and managementNature Reviews Rheumatology, 2010
- EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteriaAnnals of the Rheumatic Diseases, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals of the Rheumatic Diseases, 2008
- Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibodyArthritis & Rheumatism, 2008
- Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patientsArthritis & Rheumatism, 2007
- Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisArthritis & Rheumatism, 2004
- Takayasuʼs arteritisCurrent Opinion in Cardiology, 1994